Fabio Calabrò

4.0k citations

96 papers · 1.9k indexed · h-index 24

Impact in

Pulmonary and Respiratory Medicine top 2%
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
Oncology top 5%
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 54
- Renal cell carcinoma treatment 18
- Prostate Cancer Treatment and Research 15
- Lung Cancer Treatments and Mutations 8
Oncology 42
- Cancer Immunotherapy and Biomarkers 22

Co-authors: Cora N. Sternberg J. R. Jinkins Andrea Mancuso C. Sternberg Nicholas D. James Daniel P. Petrylak Tomasz Demkow Gary R. Hudes
Journals: Journal of Clinical Oncology (18 papers)Annals of Oncology (7 papers)European Urology (4 papers)World Journal of Urology (4 papers)Lung Cancer (3 papers)
Partner nations: Italy United States France

In The Last Decade

Fabio Calabrò

88 papers receiving 1.9k citations

Peers

Countries citing papers authored by Fabio Calabrò

Since Specialization

Citations

This map shows the geographic impact of Fabio Calabrò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Calabrò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Calabrò more than expected).

Fields of papers citing papers by Fabio Calabrò

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Calabrò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Calabrò. The network helps show where Fabio Calabrò may publish in the future.

Co-authors

The 25 scholars most cited alongside Fabio Calabrò, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fabio Calabrò Line = papers co-authored together Fabio Calabrò links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy Technology in Cancer Research & Treatment ·Ria Nagpal, Marina Campione, Sara Elena Rebuzzi, Lucia Fratino, Pasquale Rescigno, Sergio Bracarda, Davide Bimbatti, Ugo De Giorgi, Matteo Santoni, Fabio Calabrò, Mimma Rizzo, Alessio Signori, Diana Giannarelli, Giuseppe Fornarini, Umberto Basso, Giuseppe Luigi Banna	2025	1
2	Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design The Lancet ·Alberto Bossi, Stéphanie Foulon, Xavier Maldonado, Paul Sargos, Róisín MacDermott, Paul Kelly, Aude Fléchon, Bertrand Tombal, S. Supiot, Dominik Berthold, Philippe Ronchin, Gabriel Kacsó, Naji Salem, Fabio Calabrò, Jean-François Berdah, Ali Hasbini, Marlon Silva, Jihane Boustani, Hélène Ribault, Karim Fizazi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2024	21
3	Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study Clinical Genitourinary Cancer ·Annalisa Guida, Alessio Gili, Claudia Mosillo, Marco Maruzzo, Eleonora Lai, Francesco Pierantoni, Davide Bimbatti, Umberto Basso, Giuseppe Fornarini, Sara Elena Rebuzzi, Fabio Calabrò, Linda Cerbone, Claudia Caserta, Grazia Sirgiovanni, Debora Serafin, Orazio Caffo, Sarah Scagliarini, Sergio Bracarda	2024	0
4	Stratifying the Risk of Disease Progression among Surgically Treated Muscle-Invasive Bladder Cancer Eligible for Adjuvant Nivolumab Journal of Clinical Medicine ·Rocco Simone Flammia, Gabriele Tuderti, Eugenio Bologna, Antonio Minore, Flavia Proietti, Leslie Claire Licari, Riccardo Mastroianni, Alfredo Maria Bove, Umberto Anceschi, Aldo Brassetti, Mariaconsiglia Ferriero, Salvatore Guaglianone, Giuseppe Chiacchio, Fabio Calabrò, Costantino Leonardo, Giuseppe Simone	2024	0
5	1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1 Annals of Oncology ·Elena Castro, Douglas Laird, T. Dorff, Shuang G. Zhao, Inge M. van Oort, Donatello Gasparro, Fabio Calabrò, Sandro Pignata, Lajos Géczi, Philippe Barthélémy, Deepak Kilari, J.F. Hopkins, Hsiang‐Cheng Chen, Cynthia G. Healy, Jijumon Chelliserry, Giorgio V. Scagliotti, Johann S. de Bono, N. Mehra, Karim Fizazi	2023	2
6	Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study. Journal of Clinical Oncology ·Chiara Ciccarese, Sebastiano Buti, Michela Roberto, Fabio Calabrò, Cristina Masini, Francesco Massari, Maria Antonella Cannella, Giulia Mazzaschi, Serena Astore, Stefania Di Girolamo, Martina Panebianco, Veronica Mollica, Alessia Granitto, Vincenzo Fiorentino, Francesco Pierconti, Maurizio Martini, Camillo Porta, Giampaolo Tortora, Roberto Iacovelli	2023	2
7	Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma Cancer Drug Resistance ·Serena Astore, Giulia Baciarello, Linda Cerbone, Fabio Calabrò	2023	10
8	The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort Prostate Cancer and Prostatic Diseases ·Mariaconsiglia Ferriero, Francesco Prata, Riccardo Mastroianni, Cosimo De Nunzio, Giorgia Tema, Gabriele Tuderti, Alfredo Maria Bove, Umberto Anceschi, Aldo Brassetti, Leonardo Misuraca, Silvana Giacinti, Fabio Calabrò, Salvatore Guaglianone, Andrea Tubaro, Rocco Papalia, Costantino Leonardo, Michele Gallucci, Giuseppe Simone	2022	3
9	1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial Annals of Oncology ·Gwénaëlle Gravis, X. Maldonado, Guilhem Roubaud, Ray McDermott, Aude Fléchon, Bertrand Tombal, S. Supiot, Dominik Berthold, R. Philippe, G. Kacso, Fabio Calabrò, Jean François Berdah, Ali Hasbini, M. Silva, Antoine Thiery-Vuillemin, A. Rodriguez-Vida, John A. McCaffrey, Hélène Ribault, S. Foulon, Karim Fizazi	2022	9
10	LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1 Annals of Oncology ·Karim Fizazi, Joan Carles, S. Foulon, Guilhem Roubaud, Ray McDermott, Aude Fléchon, Bertrand Tombal, S. Supiot, Dominik Berthold, Philippe Ronchin, Gabriel Kacsó, Gwénaëlle Gravis, Fabio Calabrò, Jean François Berdah, Ali Hasbini, M. Silva, Antoine Thiery-Vuillemin, I. Latorzeff, Isabelle Rieger, Alberto Bossi	2021	31
11	SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy ESMO Open ·Aristotelis Bamias, Axel S. Merseburger, Yohann Loriot, Nicholas D. James, Ernest Choy, Daniel Castellano, Fernando López‐Ríos, Fabio Calabrò, Mario W. Kramer, Guillermo de Velasco, Roubini Zakopoulou, Kimon Tzannis, Cora N. Sternberg	2021	6
12	TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway Cancer Immunology Research ·Ilaria Grazia Zizzari, Chiara Napoletano, Andrea Botticelli, S Caponnetto, Fabio Calabrò, Alain Gelibter, Aurelia Rughetti, Ilary Ruscito, Hassan Rahimi, Ernesto Rossi, Giovanni Schinzari, Paolo Marchetti, Marianna Nuti	2018	51
13	Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica Tumori Journal ·Linda Mahjoubi, Franco Cecchi, Christophe Massard, Fabio Calabrò, Anas Gazzah, Rastislav Bahleda, Philippe Jamme, Maximiliano Gelli, Diane Goèré, Ludovic Lacroix, Julien Adam, Lukas C. Heukamp, Patrizia Trenta, Todd Hembrough, Jean‐Charles Soria, Cora N. Sternberg, Michel Ducreux	2018	0
14	Metastatic bladder cancer Current Opinion in Supportive and Palliative Care ·Fabio Calabrò, Cora N. Sternberg	2012	11
15	Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer Annals of Oncology ·Cora N. Sternberg, Herlinde Dumez, Hendrik Van Poppel, Iwona Skoneczna, Avishay Sella, Gedske Daugaard, Thierry Gil, John D. Graham, P. Carpentier, Fabio Calabrò, Laurence Collette, Denis Lacombe	2009	94
16	Survival Following Complete Resection of Multifocal T4 Node-Negative NSCLC: A Retrospective Study The Thoracic and Cardiovascular Surgeon ·Alberto Terzi, G. Falezza, Cristiano Benato, Giovenzio Genestreti, Antonio Santo, Simone Furia, Birgit Feil, Fabio Calabrò	2007	5
17	Current therapies and advances in the treatment of pancreatic cancer Critical Reviews in Oncology/Hematology ·Andrea Mancuso, Fabio Calabrò, Cora N. Sternberg	2006	68
18	High-risk metastatic urothelial cancer: chances for cure? Current Opinion in Urology ·Fabio Calabrò, Cora N. Sternberg	2002	19
19	Differences in Gene Expression in Muscle– Invasive Bladder Cancer: A Comparison of Italian and American Patients European Urology ·Stephen G. Williams, Regina Gandour‐Edwards, Arline D. Deitch, SALVADOR N. TOSCANO, Juanjuan Fan, Cora N. Sternberg, Vito Pansadoro, Fabio Calabrò, Antonella Rossetti, Ralph W. deVere White	2001	9
20	MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen European Radiology ·Fabio Calabrò, J. R. Jinkins	2000	37

About Fabio Calabrò

Fabio Calabrò is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery and Urology, having authored 96 papers that have together received 1.9k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (32 papers), Urinary and Genital Oncology Studies (23 papers), Cancer Immunotherapy and Biomarkers (22 papers), Renal cell carcinoma treatment (18 papers), Cancer Genomics and Diagnostics (15 papers), Prostate Cancer Treatment and Research (15 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Lung Cancer Treatments and Mutations (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (950 citations), Oncology (689 citations), Urology (152 citations), Cancer Research (308 citations) and Surgery (680 citations). Fabio Calabrò has collaborated with scholars based in Italy, United States and France. Frequent co-authors include Cora N. Sternberg, J. R. Jinkins, Andrea Mancuso, C. Sternberg, Nicholas D. James, Daniel P. Petrylak, Tomasz Demkow, Gary R. Hudes, Michael E. Petrone and Manfred Wirth. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Urology, World Journal of Urology and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact